Chronic Hepatitis B, C Linked With Non-Hodgkin Lymphoma in HIV Patients
Chronic infection with hepatitis B or C virus was associated with an increased risk for non-Hodgkin lymphoma among patients with HIV who are on antiretroviral therapy.
Androgens May Have Role in Treating Elderly AML Patients
Maintenance therapy with norethandrolone significantly improved survival in elderly patients with acute myeloid leukemia without increasing toxicity.
Cost of TKIs May Be Deterrant in CML Patients on Medicare
An analysis of tyrosine kinase inhibitor initiation and adherence in Medicare beneficiaries with chronic myeloid leukemia suggests that out-of-pocket costs may be a barrier to treatment.
Frontline High-Dose Chemo Fails to Improve High-Risk DLBCL Outcomes
Frontline intensive therapy with rituximab plus high-dose sequential chemotherapy did not improve outcomes for high-risk patients with DLBCL compared with treatment with R-CHOP-14.
The Emerging Role of Checkpoint Inhibitor Therapy in Hodgkin Lymphoma
Ultimately, the management goal is not for patients with relapsed/refractory disease to live with chronic Hodgkin lymphoma while receiving immune checkpoint blockade therapy, but rather to cure more patients with first- or second-line therapy.
Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
In this article we review the scientific rationale, preclinical evidence, and most recent clinical data for the use of checkpoint inhibitor therapy in patients with relapsed Hodgkin lymphoma.
The Limitations and Promise of Immunotherapy With Chimeric Antigen–Modified T Cells
Identification of effective lymphodepletion strategies, optimization of patient selection, and management of novel toxicities remain challenges in the growing field of cellular immunotherapy.
Role of Cyclic AMP in Leukemias
In leukemias, cyclic adenosine monophosphate (cAMP) can play a role in cancer cell maturation and can be both pro- and antiapoptotic.
Anti-Malarial, Anti-Fungal Drugs Show Promise in AML
Several anti-malarial and anti-fungal drugs might be able to overcome a previously unexploited mechanism that allows some leukemia cells to escape programmed cell death.
Upfront Management of Patients With Multiple Myeloma
In this video we discuss the initial symptoms and diagnosis of multiple myeloma as well as upfront treatment with autologous stem cell transplantation and newer agents.
Shared Decision-Making in Hematologic Malignancies
In this video we discuss the goals of shared-decision making in hematologic malignancies and touch upon different scenarios where its use may be appropriate.
By clicking Accept, you agree to become a member of the UBM Medica Community.